SAN FRANCISCO, May 29, 2018 /PRNewswire/ -- Kindred Biosciences, Inc. (NASDAQ: KIN), a commercial-stage biopharmaceutical company focused on saving and improving the lives of pets, will present at the 8th Annual LD Micro Invitational Conference taking place June 4th-6th in Bel Air, CA and at the Jefferies 2018 Global Healthcare Conference taking place June 5th-8th in New York.
Richard Chin, M.D., President and Chief Executive Officer, will present and be available for one-on-one meetings. During this time, investors will have the opportunity to discuss recent developments, including the approval of KindredBio's first product, key therapeutic programs in development, and upcoming milestones.
Presentation Details:
8th Annual LD Micro Invitational Conference
Date: Tuesday, June 5, 2018
Time: 7:30 – 8 AM PDT
Location: Luxe Sunset Boulevard Hotel, Track 2
Webcast URL: Click here
Jefferies 2018 Global Healthcare Conference
Date: Friday, June 8, 2018
Time: 2 – 2.25 PM EDT
Location: Grand Hyatt, NY, Ballroom IV
Webcast URL: Click here
An archived version of the above webcasts will be available for 30 days on the Company's website.
About Kindred Biosciences
Kindred Biosciences is a commercial-stage biopharmaceutical company focused on saving and improving the lives of pets. Its mission is to bring to pets the same kinds of safe and effective medicines that human family members enjoy. The Company's strategy is to identify compounds and targets that have already demonstrated safety and efficacy in humans and to develop therapeutics based on these validated compounds and targets for dogs, cats and horses. The Company has a deep pipeline of novel drugs and biologics in development across many therapeutic classes. KindredBio's first approved drug is Mirataz™ (mirtazapine transdermal ointment) for the management of weight loss in cats.
For more information or to download the corporate presentation, visit www.KindredBio.com/LearnMore. Stay connected with KindredBio on Facebook at www.Facebook.com/KindredBio.
Contact
Russell Radefeld
KindredBio
russell.radefeld@kindredbio.com
(650) 701-7904
SOURCE Kindred Biosciences, Inc.